ClinicalTrials.Veeva

Menu

Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

U

University of Chinese Academy Sciences

Status and phase

Completed
Phase 4

Conditions

Bronchoesophageal Fistula
General Anesthetic Drug Adverse Reaction
Endobronchial Metastases

Treatments

Drug: Sugammadex Sodium
Drug: Flumazenil
Drug: Rocuronium
Drug: Propofol
Drug: Remifentanil
Drug: oxycodone
Drug: Remimazolam

Study type

Interventional

Funder types

Other

Identifiers

NCT05468671
IRB-2020-406

Details and patient eligibility

About

This study is a prospective, randomized, controlled trial. In this study, 30 patients who underwent endotracheal tumor resection under rigid bronchoscope or stent placement for acquired tracheoesophageal fistula were selected as the subjects. The patients were randomly divided into remazolam general anesthesia group (R group) and propofol general anesthesia control group (P group). Remazolam general anesthesia group (R group): Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction. Propofol general anesthesia control group (P group): Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia. After induction, high-frequency jet ventilation was used in both groups, the respiratory rate was 30-60 times/min, the inspiratory-to-breath ratio was 1:2, and the driving pressure was 0.8-1.0 KPa. Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance. Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance. The dosage of propofol or remazolam was adjusted according to BIS and intraoperative hemodynamic changes. Rocuronium bromide 10 mg was added every half hour. Intraoperative application of vasoactive drugs to maintain mean arterial pressure above 60mmHg to avoid perioperative hypotension. Blood oxygen saturation and end-tidal carbon dioxide were monitored to avoid perioperative hypoxemia and hypercapnia, and warm measures were used to maintain the patient's intraoperative body temperature above 36.0°C. After surgery, group R was treated with sugammadex sodium 2-4 mg/kg to antagonize rocuronium bromide, and 0.5 mg of flumazenil was used to antagonize remazolam by intravenous injection; group P was treated with sugammadex 2-4 mg/kg to antagonize rocuronium.

Enrollment

34 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing bronchoscopy endotracheal tumor resection or stenting of acquired tracheoesophageal fistula within a limited time
  • >18 Years
  • ASA Ⅱ-Ⅳ

Exclusion criteria

  • <18Years
  • Refuse to participate
  • A history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis;
  • Severe hepatic dysfunction (Child-Pugh class C)
  • Severe renal dysfunction (requiring dialysis)
  • Patients with ASA grade Ⅴ and above
  • Emergency Surgery

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

34 participants in 2 patient groups

Remazolam general anesthesia group (R group)
Experimental group
Description:
Remazolam 0.4 mg/kg, oxycodone 0.2 mg/kg and rocuronium 0.9 mg/kg were given for anesthesia induction.Group R was given remazolam 1mg/kg/h and remifentanil 6-8ug/kg/h for maintenance.
Treatment:
Drug: Flumazenil
Drug: Rocuronium
Drug: Remifentanil
Drug: Remimazolam
Drug: Sugammadex Sodium
Drug: oxycodone
Propofol general anesthesia control group (P group)
Active Comparator group
Description:
Propofol 1.5mg/kg, oxycodone 0.2mg/kg and rocuronium 0.9mg/kg were given for induction of anesthesia.Group P was given propofol 4-8 mg/kg/h and remifentanil 6-8ug/kg/h for anesthesia maintenance.
Treatment:
Drug: Rocuronium
Drug: Propofol
Drug: Remifentanil
Drug: Sugammadex Sodium
Drug: oxycodone

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems